NCT01636739View on ClinicalTrials.gov

Special Drug Use Investigation for ROTARIX®

CompletedOBSERVATIONAL
Enrollment

10,982

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Infections, Rotavirus
Interventions
BIOLOGICAL

Oral Rotarix®

2 doses administered orally.

OTHER

Data collection

Additional information on intussusception will be collected through interview and by phone-contact.

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01636739 - Special Drug Use Investigation for ROTARIX® | Biotech Hunter | Biotech Hunter